J
Juliann Chmielecki
Researcher at AstraZeneca
Publications - 124
Citations - 16230
Juliann Chmielecki is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 45, co-authored 117 publications receiving 12742 citations. Previous affiliations of Juliann Chmielecki include Massachusetts Institute of Technology & Broad Institute.
Papers
More filters
Journal ArticleDOI
Therapeutic insights for malignant phyllodes from next-generation sequencing.
Kim M. Hirshfield,Christiaan Devries,Aleksander Chojecki,Siraj M. Ali,Roman Yelensky,Juliann Chmielecki,Jeffrey S. Ross,Philip J. Stephens,Vincent A. Miller,Lorna Rodriguez,Shridar Ganesan +10 more
TL;DR: The immune response to phyllodes tumors of the breast has resulted in the primary therapeutic goal of obtaining negative surgical margins being achieved, and the number of patients with positive surgical margins has increased significantly.
Journal ArticleDOI
Analysis of BRAF alterations and molecular profiling in glioblastoma and astrocytoma.
Nadia Faiq,Juliann Chmielecki,Michael E. Goldberg,Phil Stephens,Razelle Kurzrock,Santosh Kesari,David Piccioni +6 more
TL;DR: Characterization of BRAF mutations in glioblastoma and astrocytoma may identify a subgroup of patients with sensitivity to BRAF inhibitors, and this work may help clarify the rationale behind the continued presence of these mutations in patients with GBM.
Proceedings ArticleDOI
Abstract P6-07-08: The complete spectrum ofESR1mutations from 7590 breast cancer tumor samples
Jill M. Spoerke,Erica B. Schleifman,Travis A. Clark,Geneva Young,Michelle Nahas,Mark Kennedy,Leonie S. Young,Juliann Chmielecki,Geoff Otto,Doron Lipson,Timothy R. Wilson,Steven Gendreau,Lackner +12 more
TL;DR: The mutational landscape of ESR1 and co-occurring alterations is important for diagnostic development in conjunction with the clinical development of novel anti-endocrine therapies, and the data demonstrate a large spectrum of mutations in the LBD in addition to known hotspot mutations.
Journal ArticleDOI
Targeted next-generation sequencing (NGS) of carcinoma of unknown primary site (CUP): Actionable genomic alterations (GA) and new routes to targeted therapies.
Jeffrey S. Ross,Kai Wang,Geoff Otto,Gary A. Palmer,Roman Yelensky,Doron Lipson,Juliann Chmielecki,Siraj M. Ali,Deborah Morosini,Vincent A. Miller,Phil Stephens +10 more
TL;DR: NGS was performed to identify potential therapeutic targets not currently tested for in routine care of CUP patients to identify Actionable alterations, those for which cancer drugs on the market or in registered clinical trials could be identified.
Proceedings ArticleDOI
Abstract A79: Comprehensive genomic profiling (CGP) of adult granulosa cell tumors (aGCT) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options
M. Rowland,Scott McMeekin,Kathleen N. Moore,Mark Bailey,Siraj M. Ali,Rosemary E. Zuna,Jo-Anne Vergilio,James Suh,Juliann Chmielecki,Garrett M. Frampton,Doron Lipson,Philip J. Stephens,Vincent A. Miller,Jeffrey S. Ross,Julia A. Elvin +14 more
TL;DR: Complete genomic profiling (CGP) of adult granulosa cell tumors (aGCT) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options and demonstrates potential efficacy of an AKT inhibitor in a subset of patients suffering from this otherwise treatment refractory tumor.